TP53 and cancer: Generally, the transition from wild-type p53 to a mutant phenotype results in mutant p53 protein overexpression due to the resistance to murine double minute gene 2 (MDM2)-mediated degradation and subsequent abnormal stability of the mutant protein; therefore, immunohistochemistry (IHC) can be used to determine the expression and location of mutant p53 protein that has accumulated in the cell nuclei of cancer tissues [12,13].